CClinicalTrials.gg
Sign In
Not yet recruitingNCT05770323Updated Mar 15, 2023

Association Between Uric Acid and Acute Coronary Syndrome

An observational study in Acute Coronary Syndrome, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 7 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to acess the association between admission serum uric acid level and in_hospital outcomes in patients with acute coronary syndromes

Read the detailed description

Prospective study

  1. To acess patients with acute coronary syndrome including one of (typical Chest pain _ECGchanges _elevated cardic enzyme)
  2. the complication occur in patients with hyperurecemia and those with normal uric acid
02

Conditions studied

  • Acute Coronary Syndrome
03

In context

Acute Coronary Syndrome

1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.

This study's planned enrollment of 150 is below the median of 500 across 561 observational studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All Patient admited to sohag University in CCU with acute coronary syndrome

Inclusion criteria

all patients with acute coronary syndrome with one of the Following

  • Typical Chest pain
  • ECG changes
  • Elevated cardiac enzyme

Exclusion criteria

Exclusion Criteria:

  • patients aged less than 18 years
  • patients with gout
  • patients with treated with diuretics
  • Patient with CKD
  • Patient with chronic haemolytic anemia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with normal uric acid levels

    Patient with uric acid level (2.5_6)for femal and (3_7)for males

    Diagnostic Test: Uric acid level

  • Patients with elevated uric acid level (hyperurecemia)

    Uric acid level more than 7 for males and more than 6 for female

    Diagnostic Test: Uric acid level

Interventions

  • Diagnostic testUric acid level

    Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed

06

What researchers measure

Primary outcomes

  1. Association between serum uric acid level and acute coronary syndrome in hospital outcomes

    Comparision between Patient with hyperurecemia and those with normal uric acid level

    Time frame: From the day of admission and 30 days post discharge

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Maloberti A, Biolcati M, Ruzzenenti G, Giani V, Leidi F, Monticelli M, Algeri M, Scarpellini S, Nava S, Soriano F, Oreglia J, Sacco A, Morici N, Oliva F, Piani F, Borghi C, Giannattasio C. The Role of Uric Acid in Acute and Chronic Coronary Syndromes. J Clin Med. 2021 Oct 16;10(20):4750. doi: 10.3390/jcm10204750. PubMed 34682873 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05770323
Lead sponsor
Sohag University
Responsible party
Hadeer Hassan Abdelaty (Resident doctor at sohag University, Sohag University) — Principal investigator
First posted
Mar 15, 2023
Start date
Mar 22, 2023 (estimated)
Primary completion
Feb 22, 2024 (estimated)
Completion
Mar 22, 2024 (estimated)
Last update
Mar 15, 2023

Study contacts

Hadeer H Abdelaty
Contact
Hadirhassan@med.sohag.edu.eg
01128222324
Hassan A Hassanin
Contact
01003459741

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Coronary Syndrome→

Other studies from this sponsor

Sohag University

Start the discussion